Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus second-line chemotherapy for locally recurrent or metastatic breast cancer
ChiCTR-OPC-17012933Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Oct 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of latanoprost in breast cancer, sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: progression-free survival. Started Oct 2017; status: recruiting.
02
Drugs
latanoprost
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR-OPC-17012933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17012933.